2023-509387-24-00已完成2 期
“A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate cancer”
Medica Scientia Innovation Research S.L.8 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2024年8月20日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 8
- 主要终点
- PSA-CR defined as the percentage of patients with PSA < 0.2 ng/mL at month 12 of therapy.
研究概览
简要总结
To evaluate the antitumor activity of talazoparib (PF-06944076) in combination with enzalutamide and ADT –as determined by the confirmed prostate-specific antigen-complete response (PSA-CR)– in patients with mHNPC.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Adult patients (>18 y.o.) who signed informed consent form (ICF) prior to participation in any study-related activities.
- •Patients must agree to use a condom when is engaged in sexual activity with a pregnant woman during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after last dose of talazoparib (PF-06944076), whichever occurs later. Patients must also agree to use an additional highly effective form of contraception or two effective contraceptive methods, when is engaged in sexual intercourse with a woman of childbearing potential during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after last dose of talazoparib (PF-06944076), whichever occurs later
- •Must agree to refrain to donate sperm during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after last dose of talazoparib (PF-06944076), whichever occurs later.
- •PSA ³ 4 ng/mL at diagnosis or before starting ADT therapy.
- •Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
- •High-volume metastatic disease documented on bone scan or computed tomography (CT)/magnetic resonance imaging (MRI) scan, defined as the presence of either visceral disease and/or at least four bone metastases on bone scan, with at least one of them beyond spine/pelvis.
- •Life expectancy of ≥ 12 months.
- •Histologically confirmed adenocarcinoma of the prostate without predominance of small-cell or neuroendocrine features according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines based on local testing on the most recent analyzed biopsy. Note: Central confirmation of adenocarcinoma is not required for study entry. However, tissue blocks, or slides, must be submitted to confirm the diagnoses by a Sponsor-designated central laboratory retrospectively and/or exploratory biomarker analyses.
- •Willingness and ability to provide tumor paired biopsies during the study participation in order to perform exploratory studies. At the study entry, the most recent tumor biopsy since last progression from either metastatic or primary tissues will be provided. If not feasible, patient eligibility should be evaluated by a Sponsor’s qualified designee.
- •Adequate hematologic and organ function within 28 days before the first study treatment on Cycle 1 Day 1, defined by the following: a. Hematological: i. White blood cell (WBC) count > 3.0 x 109/L; ii. Absolute neutrophil count (ANC) > 1.5 x 109/L; iii. Platelet count > 100.0 x109/L; iv. Hemoglobin (Hb) > 9.0 g/dL. Note: Patients receiving growth factors or blood transfusions within 14 days before obtaining the hematology values at screening will be excluded. b. Hepatic: i. Total bilirubin ≤ 1.5 times the upper limit of normal (× ULN) (≤ 3 x ULN in the case of Gilbert’s disease); ii. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN (in the case of liver metastases ≤ 5 × ULN); iii. Alkaline phosphatase (ALP) ≤ 2.5 × ULN (≤ 5 × ULN in the case of liver and/or bone metastases). c. Renal: i. Serum creatinine < 1.5 × ULN or creatinine clearance ≥ 30 mL/min based on Cockcroft−Gault glomerular filtration rate estimation. d. Coagulation: i. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless on medication known to alter INR and/or aPTT. e. Nutritional status: i. Serum Albumin ≥ 2.8 g/dL.
- •Bisphosphonates or denosumab dosage must have been stable for at least 4 weeks before Day 1 for patients receiving these therapies.
排除标准
- •Prior treatment with enzalutamide, apalutamide, darolutamide or abiraterone acetate.
- •Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 14 days of start of study drugs, or patients who have not recovered from the side effects of any major surgery.
- •History of another malignancy within three years of study enrollment with the exception of carcinoma in situ, non-melanoma skin carcinoma, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the Sponsor’s Medical Monitor is required, or any concurrent malignancy for which the patient is receiving therapy
- •Active uncontrolled infection at the time of enrollment.
- •Congenital long QT syndrome or Electrocardiogram (ECG) at screening with QT interval corrected using Fridericia's formula (QTcF) > 500 milliseconds.
- •Patients with clinically significant cardiovascular disease including but not limited to any of the following: a. Stroke, transient ischemic attack, unstable angina pectoris, or documented myocardial infarction within 12 months prior to study entry. b. Symptomatic pericarditis or clinically significant pericardial effusion or myocarditis. c. Documented congestive heart failure (New York Heart Association functional classification III- IV). d. Uncontrolled, persistent hypertension defined as systolic blood pressure > 170 mmHg or diastolic blood pressure > 100 mmHg.
- •Patients have any of the following cardiac conduction abnormalities: a. Ventricular arrhythmias except for benign premature ventricular contractions. b. Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication. c. Conduction abnormality requiring a pacemaker. d. Other cardiac arrhythmia not controlled with medication.
- •Patients have any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator’s judgment contraindicate patient participation in the clinical study.
- •Treatment with estrogens, cyprotoerone acetate or glucocorticoids (at a dose greater than the equivalent to 10 mg/day of prednisone) in the 4 weeks prior to scheduled Day 1 of treatment.
- •Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are employees of the trial sponsor, including their family members, directly involved in the conduct of the study.
- •Concurrent participation in other clinical trial, except other translational studies or observational studies (defined as those with no therapeutic intervention)
- •History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.
- •Known hypersensitivity to recombinant proteins, or any excipient contained in the drug formulation for talazoparib (PF-06944076) and enzalutamide.
- •Prior systemic therapy for metastatic prostate cancer (mPCa). Note: Initiation of androgen deprivation therapy (ADT) within 4 weeks prior to study entry would be allowed (with or without first-generation antiandrogens), providing a tumor biopsy sample was taken prior to initiation of ADT is made available for biomarker studies and upon approval by the sponsor. If patient was started on first-generation antiandrogens, these would be discontinued on prior to randomization. Note: Patients relapsing after having received an ADT-based regimen in neoadjuvant or adjuvant setting will be suitable for the study if metastatic progression occured while on non-castrate testosterone levels or at least 12 months after discontinuation of ADT
- •Treatment with approved or investigational cancer therapy within 28 days (or 5 half-lives of the drug‒ whichever is longer) prior to initiation of study treatment.
- •Known or suspected brain metastases or active leptomeningeal disease
- •Symptomatic or impending spinal cord compression or cauda equina syndrome.
- •Subject has a history of seizure or any condition that may predispose to seizure (i.e. prior significant brain trauma, brain vascular malformations, …), or subjects that have had unexplained loss of consciousness or transient ischemic attacks within 1 year prior to scheduled Day 1 of treatment.
- •Therapeutic radiation therapy within 14 days (seven days for limited-field palliative radiotherapy) prior to study enrolm National Cancer Insitute´s Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v.)5.0.ent, or patients who have not recovered from radiotherapy-related toxicities to grade ≤ 1 according to
结局指标
主要结局
PSA-CR defined as the percentage of patients with PSA < 0.2 ng/mL at month 12 of therapy.
PSA-CR defined as the percentage of patients with PSA < 0.2 ng/mL at month 12 of therapy.
次要结局
- Rate of PSA complete response (CR) at any time point and at month 7 (<0.2 ng/mL), PSA response (< 4ng/ml) at 7 and 12 months, PSAprogression-free survival (PSA-PFS) based on Prostate Cancer Working Group 3 (PCWG3) criteria (PSA ≥ 25% and ≥ 2 ng/mL from nadir confirmed by a second value obtained 3 or more weeks later),
- radiologic PFS (rPFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1, time to castration resistance (TTCR), based on PSA-PFS and RECIST rPFS, and overall survival (OS)
- Incidence of adverse events (AEs), incidence of prespecified AEs as per National Cancer Insitute’s Common Terminology Criteria for Adverse Events (CTCAE) v.5.0, change from baseline in targeted vital signs, and change from baseline in targeted clinical laboratory test results.
研究者
Alicia Garcia
Scientific
Medica Scientia Innovation Research S.L.
研究点 (8)
Loading locations...
相似试验
招募中
2 期
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150Hoffmann-La Roche100
招募中
3 期
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerNCT07276399Janssen Research & Development, LLC500
招募中
2 期
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesChronic Lymphocytic LeukemiaNCT07271667Curis, Inc.108
已完成
2 期
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.2024-519451-29-00Grupo Espanol Multidisciplinar De Melanoma16
招募中
3 期
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL )2024-519345-30-00Biogen Idec Research Limited201